Hallmarks of pancreatic cancer: spotlight on TAM receptors

Pancreatic ductal adenocarcinoma (PDAC) represents the most prevalent type of pancreatic cancer and ranks among the most aggressive tumours, with a 5-year survival rate of less than 11%. Projections indicate that by 2030, it will become the second leading cause of cancer-related deaths. PDAC present...

ver descrição completa

Detalhes bibliográficos
Autores: Vázquez-Bellón, Núria, Martínez Bosch, Neus, García de Frutos, Pablo, Navarro Medrano, Pilar
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/70184
Acesso em linha:http://hdl.handle.net/10230/70184
http://dx.doi.org/10.1016/j.ebiom.2024.105278
Access Level:acceso abierto
Palavra-chave:Diagnosis
PDAC
Pancreatic cancer
TAM receptors
Treatment
id ES_8cd73435031bfadc8a2e8520efa2ba26
oai_identifier_str oai:recercat.cat:10230/70184
network_acronym_str ES
network_name_str España
repository_id_str
spelling Hallmarks of pancreatic cancer: spotlight on TAM receptorsVázquez-Bellón, NúriaMartínez Bosch, NeusGarcía de Frutos, PabloNavarro Medrano, PilarDiagnosisPDACPancreatic cancerTAM receptorsTreatmentPancreatic ductal adenocarcinoma (PDAC) represents the most prevalent type of pancreatic cancer and ranks among the most aggressive tumours, with a 5-year survival rate of less than 11%. Projections indicate that by 2030, it will become the second leading cause of cancer-related deaths. PDAC presents distinctive hallmarks contributing to its dismal prognosis: (i) late diagnosis, (ii) heterogenous and complex mutational landscape, (iii) high metastatic potential, (iv) dense fibrotic stroma, (v) immunosuppressive microenvironment, and (vi) high resistance to therapy. Mounting evidence has shown a role for TAM (Tyro3, AXL, MerTK) family of tyrosine kinase receptors in PDAC initiation and progression. This review aims to describe the impact of TAM receptors on the defining hallmarks of PDAC and discuss potential future directions using these proteins as novel biomarkers for early diagnosis and targets for precision therapy in PDAC, an urgent unmet clinical need.This work was supported by grants from the Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) (PI20/00625 and PI23/00591) to PN, 8th “Beca Carmen Delgado” to PN and PGF and grants from the MICIU (PID2021-123564OB-100) to PGF. The funders did not have any role in paper design, data collection, data analysis, interpretation, or writing of the paper. NV-B is supported by a FPU (“Formación de Profesorado Universitario”) predoctoral contract from the MICIU (FPU21/0928). The authors did not receive remuneration for their participation. We thank TPM Science for English proofreading and manuscript editing.Elsevier202520252024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/70184http://dx.doi.org/10.1016/j.ebiom.2024.105278http://hdl.handle.net/10230/70184reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésEBioMedicine. 2024 Sep;107:105278info:eu-repo/grantAgreement/ES/3PE/PID2021-123564OB-100© 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/701842026-05-29T05:05:01Z
dc.title.none.fl_str_mv Hallmarks of pancreatic cancer: spotlight on TAM receptors
title Hallmarks of pancreatic cancer: spotlight on TAM receptors
spellingShingle Hallmarks of pancreatic cancer: spotlight on TAM receptors
Vázquez-Bellón, Núria
Diagnosis
PDAC
Pancreatic cancer
TAM receptors
Treatment
title_short Hallmarks of pancreatic cancer: spotlight on TAM receptors
title_full Hallmarks of pancreatic cancer: spotlight on TAM receptors
title_fullStr Hallmarks of pancreatic cancer: spotlight on TAM receptors
title_full_unstemmed Hallmarks of pancreatic cancer: spotlight on TAM receptors
title_sort Hallmarks of pancreatic cancer: spotlight on TAM receptors
dc.creator.none.fl_str_mv Vázquez-Bellón, Núria
Martínez Bosch, Neus
García de Frutos, Pablo
Navarro Medrano, Pilar
author Vázquez-Bellón, Núria
author_facet Vázquez-Bellón, Núria
Martínez Bosch, Neus
García de Frutos, Pablo
Navarro Medrano, Pilar
author_role author
author2 Martínez Bosch, Neus
García de Frutos, Pablo
Navarro Medrano, Pilar
author2_role author
author
author
dc.subject.none.fl_str_mv Diagnosis
PDAC
Pancreatic cancer
TAM receptors
Treatment
topic Diagnosis
PDAC
Pancreatic cancer
TAM receptors
Treatment
description Pancreatic ductal adenocarcinoma (PDAC) represents the most prevalent type of pancreatic cancer and ranks among the most aggressive tumours, with a 5-year survival rate of less than 11%. Projections indicate that by 2030, it will become the second leading cause of cancer-related deaths. PDAC presents distinctive hallmarks contributing to its dismal prognosis: (i) late diagnosis, (ii) heterogenous and complex mutational landscape, (iii) high metastatic potential, (iv) dense fibrotic stroma, (v) immunosuppressive microenvironment, and (vi) high resistance to therapy. Mounting evidence has shown a role for TAM (Tyro3, AXL, MerTK) family of tyrosine kinase receptors in PDAC initiation and progression. This review aims to describe the impact of TAM receptors on the defining hallmarks of PDAC and discuss potential future directions using these proteins as novel biomarkers for early diagnosis and targets for precision therapy in PDAC, an urgent unmet clinical need.
publishDate 2024
dc.date.none.fl_str_mv 2024
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/70184
http://dx.doi.org/10.1016/j.ebiom.2024.105278
http://hdl.handle.net/10230/70184
url http://hdl.handle.net/10230/70184
http://dx.doi.org/10.1016/j.ebiom.2024.105278
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv EBioMedicine. 2024 Sep;107:105278
info:eu-repo/grantAgreement/ES/3PE/PID2021-123564OB-100
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412965364531200
score 15.81155

Registos relacionados